Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Neoplasia. 2010 Oct;12(10):818-25. doi: 10.1593/neo.10484.
Prostate cancer (PCa) patients receive androgen-deprivation therapy (ADT) to reduce tumor burden. However, complete eradication of PCa is unusual, and recurrent disease is evident within approximately 2 years in high-risk patients. Clinical evidence suggests that combining ADT with radiotherapy improves local control and disease-free survival in these patients compared with radiotherapy alone. We investigated whether vascularization of androgen-sensitive PCa xenografts changed after ADT and whether such therapy affected radiation response. CWR22 xenografts received combinations of ADT by castration (CWR22-cas) and 15 Gy of single-dose irradiation. At a shortest tumor diameter of 8 mm, vascularization was visualized by dynamic contrast-enhanced magnetic resonance imaging before radiation and 1 and 9 days after radiation. Voxel-wise quantitative modeling of contrast enhancement curves extracted the hemodynamic parameter K(trans), reflecting a combination of permeability, density, and blood flow. Tumor volumes and prostate-specific antigen (PSA) were monitored during the experiment. The results showed that K(trans) of CWR22-cas tumors 36±4 days after ADT was 47.1% higher than K(trans) of CWR22 tumors (P = .01). CWR22-cas tumors showed no significant changes in K(trans) after radiation, whereas K(trans) of CWR22 tumors at day 1 decreased compared with pretreatment values (P = .04) before a continuous increase from day 1 to day 9 followed (P = .01). Total PSA in blood correlated positively to tumor volume (r = 0.59, P < .01). In conclusion, androgen-exposed xenografts demonstrated radiation-induced reductions in vascularization and tumor volumes, whereas androgen-deprived xenografts showed increased vascularization and growth inhibition, but no significant additive effect of radiation.
前列腺癌 (PCa) 患者接受雄激素剥夺疗法 (ADT) 以减少肿瘤负担。然而,PCa 完全消除并不常见,高风险患者中大约 2 年内会出现复发性疾病。临床证据表明,与单独放疗相比,ADT 联合放疗可提高这些患者的局部控制率和无病生存率。我们研究了 ADT 后雄激素敏感型 PCa 异种移植物的血管生成是否发生变化,以及这种治疗是否影响放射反应。CWR22 异种移植物接受去势 (CWR22-cas) 和 15 Gy 单次剂量照射的 ADT 联合治疗。在最短肿瘤直径为 8mm 时,在放疗前和放疗后 1 天和 9 天通过动态对比增强磁共振成像观察血管生成。从对比增强曲线中提取反映渗透性、密度和血流综合作用的血流动力学参数 K(trans)的体素定量模型。在实验过程中监测肿瘤体积和前列腺特异性抗原 (PSA)。结果表明,ADT 后 36±4 天的 CWR22-cas 肿瘤的 K(trans)比 CWR22 肿瘤的 K(trans)高 47.1% (P =.01)。CWR22-cas 肿瘤在放疗后 K(trans)无明显变化,而 CWR22 肿瘤在第 1 天的 K(trans)与预处理值相比下降 (P =.04),随后从第 1 天到第 9 天持续增加 (P =.01)。血液中的总 PSA 与肿瘤体积呈正相关 (r = 0.59,P <.01)。总之,暴露于雄激素的异种移植物显示出放射诱导的血管生成和肿瘤体积减少,而雄激素剥夺的异种移植物显示出血管生成增加和生长抑制,但放射无显著的附加作用。